Stay updated on Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial
Sign up to get notified when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.

Latest updates to the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRecruitment status updated to 'No longer looking for participants,' indicating termination due to low enrollment. The study record version updated to v3.6.0, replacing the previous v3.5.5.SummaryDifference0.4%

- Check16 days agoChange DetectedA new revision tag v3.5.5 is added to the page history, replacing v3.5.4, indicating an update to the record.SummaryDifference0.1%

- Check38 days agoChange DetectedAdded a new revision entry v3.5.4 to the record history. The previous revision v3.5.3 was removed from the history.SummaryDifference0.1%

- Check59 days agoChange DetectedA page revision/version identifier was updated from v3.5.2 to v3.5.3 on the study’s record history page.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check95 days agoChange DetectedRevision: v3.5.0 was added to the Record History and Revision: v3.4.3 was removed.SummaryDifference0.1%

Stay in the know with updates to Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.